Mitochondrial dysfunction has been implicated in a variety of human diseases, including cancer and neurodegenerative disorders. EŠective medical therapies for such diseases will ultimately require the targeted delivery of therapeutic agents to mitochondria. This will likely be achieved through innovations in the areas of the nanotechnology of intracellular tra‹cking. Mitochondrial delivery systems for a variety of cargoes have been repored to date. However, only a limited number of approaches are available for delivering macromolecules directly to mitochondria. We previously reported on the construction of a MITO-Porter, a liposome-based carrier that introduces macromolecular cargos into mitochondria via membrane fusion. Using the green ‰uorescence protein as a model macromolecule in conjunction with analysis by confocal laser scanning microscopy, we were able to conˆrm the mitochondrial delivery of a macromolecule by the MITO-Porter. Moreover, we reported that the Dual Function MITO-Porter (DF-MITO-Porter) could e‹ciently deliver cargo to mitochondria, through endosomal and mitochondrial membranes via step-wise membrane fusion. Here, We will present ourˆndings on the development of our mitochondrial drug delivery system, and discuss our attempts regarding mitochondrial gene delivery and therapy. Finally, We will discuss the potential use of mitochondrial drug delivery systems in mitochondrial medicine.
The MITO-Porter is surface-modiˆed with a high density of R8, which permits it to be internalized by cells via macropinocytosis. R8 can escape from macropinosomes to the cytosol, which prevents lysosomal degradation. When the MITO-Porter reaches the cytosol, it can bind to mitochondria via electrostatic interactions with R8. Encapsulated compounds are delivered to the intramitochondrial compartment via fusogenic lipids that fuse to the mitochondrial membrane. OM, outer membrane; IMS, intermembrane space; IM, inner membrane. A, Thisˆgure illustrates the experimental protocol. GFP or GFP-encapsulating carriers were incubated with mitochondria (1), and the mitochondria were then subfractionated into the mitochondrial outer membrane fraction (OM) and the mitochondrial intermembrane space fraction (IMS) by digitonin treatment (2). Each sample was subjected to Western blot analysis to detect GFP (3). B, Thisˆgure shows the results of a Western blot analysis. Lanes 1, 2, GFP alone; lanes 3, 4, MITO-Porter containing SM; lanes 5, 6, MITO-Porter containing PA; lanes 7, 8, R8-modiˆed liposomes composed of EPC/SM; lanes 9,10, R8-modiˆed liposomes composed of EPC/PA. Bands at 33 kDa and 28 kDa represent full-length GFP (lanes 3, 5, 7, 9) and the GFP fragment (lanes 4, 6), respectively. OM (lanes 1, 3, 5, 7, 9) and IMS (lanes 2, 4, 6, 8, 10) indicate the outer membrane and intermembrane space fractions, respectively. Complexed particles of cargos are coated with mitochondria-fusogenic lipid envelope (inner) and endosome-fusogenic lipid envelope (outer). Octaarginine (R8) functions as a cell-uptake device in the outer envelope and as a mitochondrial targeting device in the inner envelope. DNase I proteins encapsulated in the DF-MITO-Porter (SM), the DF-MITO-Porter (PA) or the control carrier with low mitochondrial fusion activity were incubated with HeLa cells. A, Cellular DNA samples were collected and then subjected to PCR. The PCR products were detected by ethidium bromide staining after separation by electrophoresis. PCR assays for the ND6 and b-actin genes detection were performed in order to detect both mtDNA 
